Essential customization options include selecting specific genetic backgrounds, modifying gene expression levels, and tailoring phenotypic traits to align with the research objectives. We work closely with clients to ensure that the model meets their precise experimental needs.

Our collaborations with researchers have led to significant advancements in gene therapy and pharmacological interventions. For example, studies using our models have contributed to the development of gene therapies that are currently undergoing clinical trials, showcasing the translational potential of our work.

We employ rigorous validation processes that include phenotypic characterization, functional assessments, and comparisons with clinical data. This ensures that our models exhibit the same pathological features observed in human patients, providing confidence in their utility for research.

Our mouse models often include genetic modifications such as knockouts or transgenic alterations relevant to specific ocular diseases. For instance, we utilize models with mutations in genes like RPE65 or ABCA4, which are associated with inherited retinal diseases, to provide a more accurate representation of human conditions.

At Cyagen, we offer a range of ocular disease models, including those for retinal degeneration, diabetic retinopathy, and age-related macular degeneration. These models are designed to closely mimic the human disease state, allowing researchers to study the underlying mechanisms and test potential therapies effectively.

The lead time for developing custom neurological disease models can vary depending on the complexity of the genetic modifications and the specific disease. For less common conditions like frontotemporal dementia, we typically require 6 to 12 months from project initiation to delivery, assuming standard genetic engineering techniques are used. Complex models might take longer. We encourage early consultation to discuss project specifics and timelines.